Page 108 - Read Online

Page 18 of 18 Karademir. Hepatoma Res 2018;4:58 I http://dx.doi.org/10.20517/2394-5079.2018.40

Japan integrated staging score. Intervirology 2008;51 Suppl 1:86-94.
59. Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, Mok TS, Yeo W. Prospective
validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian
population. J Gastroenterol Hepatol 2011;26:340-7.
60. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T. Staging hepatocellular carcinoma by a novel scoring system
(BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006;4:1528-36.
61. Fox R, Berhane S, Teng M, Cox T, Tada T, Toyoda H, Kumada T, Kagebayashi C, Satomura S, Johnson PJ. Biomarker-based prognosis in
hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer 2014;110:2090-8.
62. Chan SL, Mo F, Johnson P, Li L, Tang N, Loong H, Chan AW, Koh J, Chan AT, Yeo W. Applicability of BALAD score in prognostication of
hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2015;30:1529-35.
63. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD. A new prognostic model for
hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010;53:108-17.
64. Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805.
65. Kim BH, Park JW, Nam BH, Kwak HW, Kim WR. Validation of a model to estimate survival in ambulatory patients with hepatocellular
carcinoma: a single-centre cohort study. Liver Int 2014;34:e317-23.
66. Adhoute X, Penaranda G, Bronowicki JP, Raoul JL. Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. J
Hepatol 2015;62:492-3.
67. Kolly P, Reeves H, Sangro B, Knöpfli M, Candinas D, Dufour JF. Assessment of the Hong Kong Liver Cancer Staging System in Europe.
Liver Int 2016;36:911-7.
68. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini
GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati
Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group. Development and validation of a new prognostic system for
patients with hepatocellular carcinoma. PLoS Med 2016;13:e1002006.
69. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.
Gastroenterology 2004;127:S108-12.
70. Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta 2013;425:212-20.
71. Zhao Y, Wang M, Cui C, Zhang L, Liao F, Li H, Wu X. Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers
in diagnosis of small primary hepatocellular carcinoma. Cancer Biomark 2015;15:677-83.
72. Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, lens culinaris agglutinin-reactive
fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. Hepatol Res 2016;46:E130-5.
73. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in
patients with hepatocellular carcinoma. Br J Surg 2004;91:1354-60.
74. Zhan P, Qian Q, Yu LK. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a metaanalysis.
Hepatobiliary Surg Nutr 2013;2:209-15.
75. Yuen MF, Lai CL.Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005;19:91-9.
76. Hu J, Xu Y, Shen ZZ, Wang Z, Lu Q, Yang GH, Ding ZB, Fan J, Zhou J. High expressions of vascular endothelial growth factor and
platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after
curative resection. J Cancer Res Clin Oncol 2009;135:1359-67.